|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: EML3 |
Gene summary for EML3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | EML3 | Gene ID | 256364 |
| Gene name | EMAP like 3 | |
| Gene Alias | ELP95 | |
| Cytomap | 11q12.3 | |
| Gene Type | protein-coding | GO ID | GO:0000070 | UniProtAcc | Q32P44 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 256364 | EML3 | LZE2T | Human | Esophagus | ESCC | 2.53e-05 | 4.06e-01 | 0.082 |
| 256364 | EML3 | LZE4T | Human | Esophagus | ESCC | 8.02e-04 | 8.18e-02 | 0.0811 |
| 256364 | EML3 | LZE20T | Human | Esophagus | ESCC | 2.76e-04 | 1.27e-01 | 0.0662 |
| 256364 | EML3 | LZE24T | Human | Esophagus | ESCC | 7.03e-12 | 1.59e-01 | 0.0596 |
| 256364 | EML3 | P1T-E | Human | Esophagus | ESCC | 2.21e-06 | 2.36e-01 | 0.0875 |
| 256364 | EML3 | P2T-E | Human | Esophagus | ESCC | 8.02e-21 | 2.32e-01 | 0.1177 |
| 256364 | EML3 | P4T-E | Human | Esophagus | ESCC | 6.74e-09 | 2.92e-01 | 0.1323 |
| 256364 | EML3 | P5T-E | Human | Esophagus | ESCC | 7.47e-06 | 7.02e-02 | 0.1327 |
| 256364 | EML3 | P8T-E | Human | Esophagus | ESCC | 2.47e-26 | 4.38e-01 | 0.0889 |
| 256364 | EML3 | P9T-E | Human | Esophagus | ESCC | 1.70e-13 | 2.12e-01 | 0.1131 |
| 256364 | EML3 | P10T-E | Human | Esophagus | ESCC | 6.66e-20 | 1.01e-01 | 0.116 |
| 256364 | EML3 | P11T-E | Human | Esophagus | ESCC | 1.58e-11 | 3.55e-01 | 0.1426 |
| 256364 | EML3 | P12T-E | Human | Esophagus | ESCC | 9.46e-15 | 1.80e-01 | 0.1122 |
| 256364 | EML3 | P15T-E | Human | Esophagus | ESCC | 5.43e-06 | 7.47e-02 | 0.1149 |
| 256364 | EML3 | P16T-E | Human | Esophagus | ESCC | 1.22e-05 | 1.05e-01 | 0.1153 |
| 256364 | EML3 | P17T-E | Human | Esophagus | ESCC | 1.91e-04 | 2.84e-01 | 0.1278 |
| 256364 | EML3 | P19T-E | Human | Esophagus | ESCC | 3.29e-06 | 3.45e-01 | 0.1662 |
| 256364 | EML3 | P20T-E | Human | Esophagus | ESCC | 2.63e-16 | 3.25e-01 | 0.1124 |
| 256364 | EML3 | P21T-E | Human | Esophagus | ESCC | 2.85e-20 | 4.93e-01 | 0.1617 |
| 256364 | EML3 | P22T-E | Human | Esophagus | ESCC | 4.08e-02 | 2.52e-02 | 0.1236 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:014001414 | Esophagus | ESCC | mitotic nuclear division | 218/8552 | 287/18723 | 6.17e-26 | 1.78e-23 | 218 |
| GO:005165617 | Esophagus | ESCC | establishment of organelle localization | 273/8552 | 390/18723 | 9.13e-23 | 1.81e-20 | 273 |
| GO:000007011 | Esophagus | ESCC | mitotic sister chromatid segregation | 138/8552 | 168/18723 | 1.37e-22 | 2.63e-20 | 138 |
| GO:00008194 | Esophagus | ESCC | sister chromatid segregation | 157/8552 | 202/18723 | 8.41e-21 | 1.33e-18 | 157 |
| GO:000705911 | Esophagus | ESCC | chromosome segregation | 238/8552 | 346/18723 | 1.72e-18 | 1.82e-16 | 238 |
| GO:190285015 | Esophagus | ESCC | microtubule cytoskeleton organization involved in mitosis | 116/8552 | 147/18723 | 1.25e-16 | 9.91e-15 | 116 |
| GO:000705214 | Esophagus | ESCC | mitotic spindle organization | 97/8552 | 120/18723 | 2.17e-15 | 1.33e-13 | 97 |
| GO:000705114 | Esophagus | ESCC | spindle organization | 134/8552 | 184/18723 | 5.70e-14 | 2.87e-12 | 134 |
| GO:005131011 | Esophagus | ESCC | metaphase plate congression | 58/8552 | 65/18723 | 1.81e-13 | 8.63e-12 | 58 |
| GO:000708011 | Esophagus | ESCC | mitotic metaphase plate congression | 47/8552 | 50/18723 | 3.15e-13 | 1.47e-11 | 47 |
| GO:00482853 | Esophagus | ESCC | organelle fission | 301/8552 | 488/18723 | 4.64e-13 | 2.12e-11 | 301 |
| GO:00988133 | Esophagus | ESCC | nuclear chromosome segregation | 187/8552 | 281/18723 | 1.00e-12 | 4.36e-11 | 187 |
| GO:005130311 | Esophagus | ESCC | establishment of chromosome localization | 67/8552 | 80/18723 | 1.92e-12 | 8.09e-11 | 67 |
| GO:005000011 | Esophagus | ESCC | chromosome localization | 68/8552 | 82/18723 | 3.37e-12 | 1.32e-10 | 68 |
| GO:00002802 | Esophagus | ESCC | nuclear division | 270/8552 | 439/18723 | 1.17e-11 | 4.24e-10 | 270 |
| GO:00512256 | Esophagus | ESCC | spindle assembly | 85/8552 | 117/18723 | 2.72e-09 | 5.98e-08 | 85 |
| GO:009030715 | Esophagus | ESCC | mitotic spindle assembly | 52/8552 | 65/18723 | 1.41e-08 | 2.77e-07 | 52 |
| GO:00705078 | Esophagus | ESCC | regulation of microtubule cytoskeleton organization | 99/8552 | 148/18723 | 1.43e-07 | 2.29e-06 | 99 |
| GO:190211514 | Esophagus | ESCC | regulation of organelle assembly | 116/8552 | 186/18723 | 3.15e-06 | 3.53e-05 | 116 |
| GO:009022413 | Esophagus | ESCC | regulation of spindle organization | 32/8552 | 39/18723 | 3.27e-06 | 3.65e-05 | 32 |
| Page: 1 2 3 4 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| EML3 | SNV | Missense_Mutation | c.562G>A | p.Glu188Lys | p.E188K | Q32P44 | protein_coding | tolerated(0.2) | benign(0.019) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
| EML3 | SNV | Missense_Mutation | novel | c.2289N>T | p.Lys763Asn | p.K763N | Q32P44 | protein_coding | tolerated(0.08) | benign(0.185) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| EML3 | SNV | Missense_Mutation | rs530217979 | c.2086N>C | p.Ala696Pro | p.A696P | Q32P44 | protein_coding | deleterious(0.02) | probably_damaging(1) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| EML3 | insertion | In_Frame_Ins | novel | c.307_308insTTTGGGCTGTAGCCCCAGGAGCTATTT | p.Ser103delinsIleTrpAlaValAlaProGlyAlaIleCys | p.S103delinsIWAVAPGAIC | Q32P44 | protein_coding | TCGA-A2-A0CP-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
| EML3 | insertion | Nonsense_Mutation | novel | c.1768_1769insGATCTACATCTATAGTGTTTCCAGTGATGGTGCCA | p.Ser590Ter | p.S590* | Q32P44 | protein_coding | TCGA-A8-A07U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | 5-fluorouracil | SD | ||
| EML3 | insertion | Frame_Shift_Ins | novel | c.705_706insACTGGAGACTCAGAGGGGAACATTCTCA | p.Leu236ThrfsTer11 | p.L236Tfs*11 | Q32P44 | protein_coding | TCGA-AN-A0FF-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| EML3 | insertion | Frame_Shift_Ins | novel | c.1288_1289insTGGGTTCGAGCAATTCTCCTGCCTCAGCCTCCCGGAG | p.His430LeufsTer97 | p.H430Lfs*97 | Q32P44 | protein_coding | TCGA-B6-A0RE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
| EML3 | insertion | Nonsense_Mutation | novel | c.969_970insAGAAGGGTAGTTCTGGGTTCATGAGGTGGGAGGTGCTAGTCTTATT | p.Gln324ArgfsTer8 | p.Q324Rfs*8 | Q32P44 | protein_coding | TCGA-C8-A12K-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| EML3 | SNV | Missense_Mutation | novel | c.2453N>A | p.Arg818His | p.R818H | Q32P44 | protein_coding | tolerated_low_confidence(0.64) | benign(0) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| EML3 | SNV | Missense_Mutation | c.1607N>A | p.Arg536His | p.R536H | Q32P44 | protein_coding | deleterious(0.02) | possibly_damaging(0.637) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |